AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02
|
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. |
See Item 5.07 below.
| ITEM 5.07 |
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. |
We held our 2017 Annual Meeting of Shareholders on March 30,
2017. At the Annual Meeting, our stockholders approved the two
proposals listed below. Based on the report of the Inspector of
Elections for the Annual Meeting, 7,441,591 shares out of
7,961,923 shares outstanding and entitled to vote, or
approximately 93.5%, were present at the meeting, in person or by
proxy. The final results for the votes regarding each proposal
are set forth in the following tables. Each of these proposals is
described in detail in the proxy statement.
| 1. | Elect four members of the Board of Directors: |
| Name | Votes For | Votes Against | Abstentions |
| James A. Joyce | 2,928,107 | 609,492 | |
| Rodney S. Kenley | 3,384,812 | 152,787 | |
| Edward G. Broenniman | 2,894,967 | 642,632 | |
| Chetan S. Shah, MD | 3,405,519 | 132,080 |
| 2. |
Ratify the appointment of Squar Milner LLP as our independent registered public accounting firm for our fiscal year ending March 31, 2017: |
| Votes For | Votes Against | Abstentions |
| 7,219,299 | 62,256 | 160,036 |
About AETHLON MEDICAL, INC. (NASDAQ:AEMD)
Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer. AETHLON MEDICAL, INC. (NASDAQ:AEMD) Recent Trading Information
AETHLON MEDICAL, INC. (NASDAQ:AEMD) closed its last trading session 00.00 at 3.41 with shares trading hands.
